CoChat
Sign Up
Cited by 67Fungal Infections and StudiesAntifungal resistance and susceptibilityActinomycetales infections and treatment

A Mycoses Study Group International Prospective Study of Phaeohyphomycosis: An Analysis of 99 Proven/Probable Cases.

Open access
Revankar, Sanjay G, Baddley, John W, Chen, Sharon C -A, Kauffman, Carol A, Slavin, Monica, Vazquez, Jose A, Seas, Carlos, Morris, Michele I +13 more·2017·Open Forum Infectious Diseases
DOI 10.1093/ofid/ofx200PMC PMC5946886
Open this paper in CoChat — free accountOpen PDF

Abstract

Background: Phaeohyphomycosis is infection caused by dematiaceous, or darkly pigmented, fungi. The spectrum of disease is broad, and optimal therapy remains poorly defined. The Mycoses Study Group established an international case registry of patients with proven/probable phaeohyphomycosis with the goal of improving the recognition and management of these infections. Methods: Patients from 18 sites in 3 countries were enrolled from 2009–2015. Cases were categorized as local superficial, local deep (pulmonary, sinus, osteoarticular infections), and disseminated infections. End points were clinical response (partial and complete) and all-cause mortality at 30 days and end of follow-up. Results: Of 99 patients, 32 had local superficial infection, 41 had local deep infection, and 26 had disseminated infection. The most common risk factors were corticosteroids, solid organ transplantation, malignancy, and diabetes. Cultures were positive in 98% of cases. All-cause mortality was 16% at 30 days and 33% at end of follow-up, and 18 of 26 (69%) with dissemination died. Itraconazole was most commonly used for local infections, and voriconazole was used for more severe infections, often in combination with terbinafine or amphotericin B. Conclusions: Phaeohyphomycosis is an increasingly recognized infection. Culture remains the most frequently used diagnostic method. Triazoles are currently the drugs of choice, often combined with other agents. Further studies are needed to develop optimal therapies for disseminated infections.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ofid/ofx200

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Among 99 cases of phaeohyphomycosis, 68% identified as white, 14% Hispanic/Latino, 8% Asian, and 7% black; the proportion of white cases increased in disseminated disease (77%), while Hispanic/Latino cases represented 28% of local-superficial disease.

    “Among 99 cases of phaeohyphomycosis (62 from the US, 7 from Australia, and 7 from Peru), 68% identified as white, 14% Hispanic/Latino, 8% Asian, and 7% black; the proportion of phaeohyphomycosis cases who were white further increased in the subgroup of disseminated disease (77%), while Hispanic/Latino cases represented 28% of those with local-superficial disease [108].”

    From Race and ethnicity: Risk factors for fungal infections? (2023) · cites this paper as [108]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Revankar, S. G., Baddley, J. W., Chen, S. C. A., Kauffman, C. A., Slavin, M., Vazquez, J. A., Seas, C., Morris, M. I., Nguyen, M. H., Shoham, S., Thompson, G. R., Alexander, B. D., Simkins, J., Ostrosky-Zeichner, L., Mullane, K., Alangaden, G., Andes, D. R., Cornely, O. A., Wahlers, K., Lockhart, S. R., & Pappas, P. G.
Affiliations
  • Wayne State University (US)
  • University of Alabama at Birmingham (US)
  • The University of Sydney (AU)
  • University of Michigan (US)
  • Melbourne Health (AU)
  • Division of Infectious Diseases, Georgia Regents University, Augusta, Georgia
  • Universidad Peruana Cayetano Heredia (PE)
  • University of Miami (US)
  • University of Pittsburgh (US)
  • Johns Hopkins University (US)
  • University of California, Davis (US)
  • Duke Medical Center (US)
  • Division of Infectious Diseases, University of Texas Health Science Center, Houston, Texas
  • University of Chicago (US)
  • Henry Ford Health (US)
  • University of Wisconsin–Madison (US)
  • University of Cologne (DE)
  • Klinikum Oldenburg (DE)
  • Centers for Disease Control and Prevention (US)
Corresponding author
Revankar, Sanjay G
ORCID
Venue
Open Forum Infectious Diseases
Publisher
Oxford University Press (OUP)
Published
2017
Volume
4
Issue
4
Pages
ofx200-ofx200
ISSN
2328-8957 (ISSN-L)
DOI
10.1093/ofid/ofx200
PMC
PMC5946886
OpenAlex
W2756890849
Cited by
67
References
26
Citations by year
2026: 7 · 2025: 5 · 2024: 11 · 2023: 8 · 2022: 6 · 2021: 8 · 2020: 12 · 2019: 8 · 2018: 2
FWCI
4.71
Type
journal article
Language
en
Open access
Licence
Locations
  • Open Forum Infectious Diseases (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by)
  • eScholarship (California Digital Library) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
  • Greater South Information System
Funders
  • Pfizer
  • OPEC Fund for International Development
  • Gilead Sciences
  • Medpace
  • Cidara Therapeutics
  • Amplyx
  • Pfizer Australia
  • Astellas Pharma
  • Centers for Disease Control and Prevention
  • MSD Australia
Topics
  • Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Microbiology › Actinomycetales infections and treatment
Keywords
phaeohyphomycosis, dematiaceous fungi, mortality, risk factors, corticosteroids, solid organ transplantation, triazole antifungal therapy, itraconazole, voriconazole, terbinafine, amphotericin B, fungal culture diagnosis, case registry

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review